terça-feira, 6 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· July 11, 2026

Ford Just Won Its First J.D. Power Quality Crown Since 2010. Here's What It Means for the Stock.

View original at nasdaq.com
Ford Just Won Its First J.D. Power Quality Crown Since 2010. Here's What It Means for the Stock. Key Points Ford ranked as the top mainstream brand in the J.D…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Ford is on track for $1 billion in material and warranty cost reductions this year.

    60% confidence
  • Full-year adjusted EBIT guidance raised to a range of $8.5 billion to $10.5 billion, up from a prior range of $8.0 billion to $10.0 billion.

    60% confidence
  • Lowering material and warranty costs and making real progress on quality is part of the company's improvement plan.

    60% confidence
  • The author believes Ford shares look attractive at current levels, though recommends keeping any position modest given the cyclical nature of the auto business.

    60% confidence
  • Management says Ford is on track to recover the Novelis-related profits in the second half of 2026.

    60% confidence

Data points we hold from this source

Ford Motor Company · margin4 percent_dividend_yield
Ford Motor Company · market share8 forward_pe_ratio
Ford Motor Company · eps3.5 USD
Ford Motor Company · margin8.1 percent
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
A nossa leitura dos dados ›
Sinais que acompanhamos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,985
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,985 factos verificados com a fonte5,351 documentos-fonte arquivados
Consulte estes dados → isubstrate.com